p8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells
Open Access
- 1 January 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (1) , 235-241
Abstract
Gemcitabine is the only available chemotherapeutic treatment of pancreatic cancers. It is, however, moderately effective, showing a tumor response rate of only 12%. The aim of this work was to identify new pathways involved in the resistance of pancreatic cancer cells to gemcitabine, in the hope of developing new adjuvant strategies to enhance its therapeutic efficacy. Comparison of gene expression patterns of five human pancreatic cancer cell lines showing different degrees of resistance to gemcitabine revealed specific overexpression of several genes in the most resistant. One of them encoded the antiapoptotic p8 protein. We found that (a) knocking down p8 expression in gemcitabine-resistant cells promoted cell death and increased caspase-3 activity; (b) forced overexpression of p8 in gemcitabine-sensitive cells increased their resistance to gemcitabine-induced apoptosis; and (c) gemcitabine down-regulated p8 mRNA expression. These results suggest that, in pancreatic cancer cells, a large part of gemcitabine-induced apoptosis results from the inhibition of the constitutive antiapoptotic activity of p8. Hence, targeting the p8-associated pathway could be a new adjuvant therapy improving the response of patients with pancreatic cancer to gemcitabine treatment.Keywords
This publication has 28 references indexed in Scilit:
- RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine ChemoresistanceClinical Cancer Research, 2005
- Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma CellsClinical Cancer Research, 2004
- Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabineInternational Journal of Cancer, 2001
- AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinomaGastroenterology, 1999
- Treatment of Duct Carcinoma of the Pancreas with the LH-RH Analogue BuserelinPancreas, 1992
- Pancreatic CarcinomaNew England Journal of Medicine, 1992
- A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancerCancer, 1991